Abbott: Parkinson Disease trials
The registry lists 17 Parkinson Disease studies with Abbott as lead sponsor. 1 are open to participants now and 4 have results posted.
Phase 2 1Phase 3 7No phase 9(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Abbott DBS Post-Market Study of Outcomes for Indications Over TimeRecruitingNCT04071847
- A Post-Market Study Evaluating the Safety of Infinity DBS System With MR Conditional LabelingCompletedNCT03884231Results posted
- Evaluation of the Infinity Deep Brain Stimulation Electrode Screening Mode ToolCompletedNCT03794661Not applicableResults posted
- Clinical Evaluation of the Infinity Deep Brain Stimulation SystemCompletedNCT02989610Results posted
- IPG Replacement Study (PREFERENCE-H)CompletedNCT02963259Results posted
- Remote Optimization, Adjustment and Measurement for Deep Brain StimulationActive, not recruitingNCT05269862Not applicable
- Post Market (Libra/LibraXP System) Deep Brain Stimulation (DBS) Parkinson's Disease StudyCompletedNCT01352819
- Post Market (Brio™ System) Deep Brain Stimulation (DBS) PD StudyWithdrawnNCT01218919
- A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.TerminatedNCT00903838Phase 2
- Deep Brain Stimulation to Treat Symptoms of Parkinson's DiseaseCompletedNCT00552474Not applicable
- An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.CompletedNCT00407095Phase 3
- SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor FluctuationsCompletedNCT00406588Phase 3
- An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD PatientsCompletedNCT00335374Phase 3
- SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson DiseaseCompletedNCT00335166Phase 3
- An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD PatientsCompletedNCT00332917Phase 3
- SLV308 for Treatment of Patients With Early Parkinson's DiseaseCompletedNCT00269516Phase 3
- Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's DiseaseCompletedNCT00134251Phase 3